BriaCell Therapeutics Stock (NASDAQ:BCTX)

Ownership Financials Chart

Previous Close

$0.59

52W Range

$0.46 - $5.97

50D Avg

$0.78

200D Avg

$1.59

Market Cap

$20.68M

Avg Vol (3M)

$4.97M

Beta

1.82

Div Yield

-

BCTX Company Profile

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

CA

Employees

16

IPO Date

Mar 14, 2012

Website

BCTX Performance

BCTX Financial Summary

	Jul 24	Jul 23	Jul 22
Revenue	-	-	-
Operating Income	$-4.79M	$-23.27M	$-15.29M
Net Income	$-4.79M	$-20.30M	$-11.58M
EBITDA	$-4.79M	$-22.37M	$-11.50M
Basic EPS	$-0.29	$-1.30	$-0.75
Diluted EPS	$-0.29	$-1.30	$-0.75

Fiscal year ends in Jul 24 | Currency in USD

Peer Comparison

Ticker	Company
XFOR	X4 Pharmaceuticals, Inc.
MREO	Mereo BioPharma Group plc
DAWN	Day One Biopharmaceuticals, Inc.
PDSB	PDS Biotechnology Corporation
HOOK	HOOKIPA Pharma Inc.
TERN	Terns Pharmaceuticals, Inc.
INZY	Inozyme Pharma, Inc.
EFTR	eFFECTOR Therapeutics, Inc.
HEPA	Hepion Pharmaceuticals, Inc.
ELEV	Elevation Oncology, Inc.